Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
Immunity|September 30, 2023
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, M Angela Aznar, Andrew J Rech, et al.
American Journal of Hematology|February 10, 2016
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftmentElizabeth O Hexner, Selina M Luger, Ran Reshef, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
Immunity|September 30, 2023
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, M Angela Aznar, Andrew J Rech, et al.
American Journal of Hematology|February 10, 2016
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftmentElizabeth O Hexner, Selina M Luger, Ran Reshef, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
The New England Journal of Medicine|October 16, 2014
Chimeric antigen receptor T cells for sustained remissions in leukemiaShannon L Maude, Noelle Frey, Pamela A Shaw, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Pageof 20